Google has requested permission from the US Environmental Protection Agency (EPA) to release up to 32 million sterilized male mosquitoes in California and Florida as part of its "Debug" program. The tech giant aims to use these insects to reduce populations of disease-carrying mosquitoes.
How the Debug Program Works
The Debug project involves rearing male mosquitoes infected with a naturally occurring bacteria called wolbachia. When these sterile males mate with wild females, their eggs do not hatch, leading to a gradual decline in the mosquito population. Male mosquitoes do not bite or transmit diseases, making this approach safe for humans.
Targeting Aedes aegypti
Google's initial efforts focus on the Aedes aegypti mosquito, which spreads dengue, Zika, yellow fever, and chikungunya. The company uses AI-powered computer vision and data analytics to separate males from females and release them in optimal locations and quantities.
EPA Review and Public Comment
The EPA is reviewing Google's request for an experimental use permit to release up to 16 million mosquitoes annually over two years. A public comment period ends on 5 June, after which the EPA will decide whether to approve the plan.
Success in Singapore
The Debug project has already shown promising results in Singapore, where releasing millions of wolbachia-infected mosquitoes led to an 80-90% suppression of the Aedes aegypti population and over a 70% reduction in dengue cases within 6 to 12 months. Google announced plans to expand the Singapore site in May.
Alternative to Pesticides
Google argues that traditional methods like pesticides are toxic and lose effectiveness over time, while clearing breeding grounds is impractical. The sterile insect technique, used for decades on various pests, offers a more sustainable solution.
Eric Caragata, an assistant professor at the University of Florida, noted that using wolbachia for sterilization has been practiced for about 15 years. The Debug project, initially a moonshot at Google X, was fully acquired by Google in December 2024 from Verily Health.
